Rajesh Bajpai, MD
Urology · Somerset, PANPI 1457902900
Payments from drug & device makers
Across 33 payments — averaging $679.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$20K
- Cook Incorporated$829
- Metuchen Pharmaceuticals$244
- Cook Medical LLC$218
- Coloplast$214
- Profound Medical Corp.$201
- plus $657 from 13 others
What the payments were for
- Grants$20,00089%
- Travel & lodging$8294%
- Food & beverage$1,5997%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $20,066 |
| Cook Incorporated | 2 | $829 |
| Metuchen Pharmaceuticals | 4 | $244 |
| Cook Medical LLC | 2 | $218 |
| Coloplast | 2 | $214 |
| Profound Medical Corp. | 1 | $201 |
| Smith+Nephew | 5 | $156 |
| Procept Biorobotics Corporation | 1 | $146 |
| Olympus America Inc. | 2 | $76 |
| Myovant Sciences Inc. | 2 | $60 |
| Foundation Medicine, Inc. | 1 | $46 |
| Koelis Inc. | 1 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Merck | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Angiodynamics, Inc. | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$20,000
- S~Curve$1,029
- Tulsa-Pro$201
- TITAN$187
- Stendra$172
- AquaBeam Robotic System$146
How this compares
$22,429 in reported general payments places this provider in the 85th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 42 | $20,053 |
| Mirabegron ErMirabegron | 20 | $11,510 |
| Tamsulosin Hcl | 400 | $5,413 |
| Methenamine Hippurate | 53 | $2,320 |
| Finasteride | 102 | $1,383 |
| Oxybutynin Chloride | 113 | $1,032 |
| Potassium Citrate ErPotassium Citrate | 23 | $926 |
| CefuroximeCefuroxime Axetil | 77 | $755 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $507 |
| Levofloxacin | 249 | $487 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $357 |
| Doxycycline Hyclate | 28 | $205 |
Paid to pharmacies, not to this prescriber.
Other urology in Somerset
- Laurence BelkoffBala Cynwyd$18.7M
- Paul SieberLancaster$12.6M
- Costas LallasPhiladelphia$3.6M
- John AndersonBethlehem$2.1M
- Jodi MaranchiePittsburgh$1.2M
- Kenneth LessansLancaster$943K
- Stanley MalkowiczPhiladelphia$882K
- Demetrius BagleyPhiladelphia$739K
- Gregory TasianPhiladelphia$645K
- Eugene PietzakPhiladelphia$544K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.